Tumor acidity and CD44 dual targeting hyaluronic acid-coated gold nanorods for combined chemo- and photothermal cancer therapy

Li, Yang; Le, Thai Minh Duy; Bui, Quang Nam; Yang, Hong Yu; Lee, Sang Soo

doi:10.1016/j.carbpol.2019.115281

Cited by 48 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2d). 87 When the pH was lower than 7.4, the de-ionization of SM in AuNRs@SM/LA-LMWHA improved the surface hydrophobicity, resulting in particle aggregation and gradually increasing size (Fig. 2e).…”

Section: Dtptas Based On Noble Metal Materialsmentioning

confidence: 98%

Dual-targeted photothermal agents for enhanced cancer therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Dtptas Based On Noble Metal Materialsmentioning

confidence: 98%

Dual-targeted photothermal agents for enhanced cancer therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Apart from CD44 itself as a promising target in cancer treatment, it has also been suggested to probably act as a biomarker for anti-tumor drug targeting to CD44-positive cancer cells [144,145]. The ubiquitin-specific protease USP22 is recognized to drive cancer invasion and metastasis as well as maintain CSCs [144].…”

Section: Cd44 and The Development Of Anti-tumor Drugsmentioning

confidence: 99%

CD44 as a tumor biomarker and therapeutic target

et al. 2020

View full text Add to dashboard Cite

CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberrant expression and dysregulation of CD44 contribute to tumor initiation and progression. CD44 represents a common biomarker of cancer stem cells, and promotes epithelial-mesenchymal transition. CD44 is involved in the regulation of diverse vital signaling pathways that modulate cancer proliferation, invasion, metastasis and therapy-resistance, and it is also modulated by a variety of molecules in cancer cells. In addition, CD44 can serve as an adverse prognostic marker among cancer population. The pleiotropic roles of CD44 in carcinoma potentially offering new molecular target for therapeutic intervention. Preclinical and clinical trials for evaluating the pharmacokinetics, efficacy and drug-related toxicity of CD44 monoclonal antibody have been carried out among tumors with CD44 expression. In this review, we focus on current data relevant to CD44, and outline CD44 structure, the regulation of CD44, functional properties of CD44 in carcinogenesis and cancer progression as well as the potential CD44-targeting therapy for cancer management.

show abstract

“…CHEMS self-assemble into a bimolecular layer in alkaline and neutral aqueous media and therefore fuse with the bimolecular layer of niosomes, whereas they rupture the bimolecular layer in acidic media to facilitating drug release ( 21 ). Intracellular and extracellular acidity has been recognized as a common feature of tumor tissue ( 22 , 23 ), and the intracellular acidity is the stronger characteristic ( 24 – 26 ). When niosomes containing CHEMS encounter tumor cells, the bimolecular layer becomes unstable due to the environmental acidity, thus promoting release of the payload ( 27 ).…”

Section: Introductionmentioning

confidence: 99%

Galactose-Modified PH-Sensitive Niosomes for Controlled Release and Hepatocellular Carcinoma Target Delivery of Tanshinone IIA

Jun

Deng

et al. 2021

AAPS PharmSciTech

View full text Add to dashboard Cite

Increasing the drug tumor-specific accumulation and controlling their release is considered one of the most effective ways to increase the efficacy of drugs. Here, we developed a vesicle system that can target hepatoma and release drugs rapidly within tumor cells. This non-ionic surfactant vesicle is biodegradable. Galactosylated stearate has been used to glycosylate the vesicles to achieve liver targeting; replacement of a portion (Chol:CHEMS = 1:1) of cholesterol by cholesteryl hemisuccinate (CHEMS) allows for a rapid release of drugs in an acidic environment. In vitro release experiments confirmed that galactose-modified pH-sensitive niosomes loaded with tanshinone IIA had excellent drug release performance in acid medium. In vitro experiments using ovarian cancer cells (A2780), colon cancer cells (HCT8), and hepatoma cell (Huh7, HepG2) confirmed that the preparation had specific targeting ability to hepatoma cells compared with free drugs, and this ability was dependent on the galactose content. Furthermore, the preparation also had a more substantial inhibitory effect on tumor cells, and subsequent apoptosis assays and cell cycle analyses further confirmed its enhanced anti-tumor effect. Results of pharmacokinetic experiments confirmed that the vesicle system could significantly extend the blood circulation time of tanshinone IIA, and the larger area under the curve indicated that the preparation had a better drug effect. Thus, the results of biodistribution experiments confirmed the in vivo liver targeting ability of this preparation. Niosomes designed in this manner are expected to be a safe and effective drug delivery system for liver cancer therapy.

show abstract

Tumor acidity and CD44 dual targeting hyaluronic acid-coated gold nanorods for combined chemo- and photothermal cancer therapy

Cited by 48 publications

References 30 publications

Dual-targeted photothermal agents for enhanced cancer therapy

Dual-targeted photothermal agents for enhanced cancer therapy

CD44 as a tumor biomarker and therapeutic target

Galactose-Modified PH-Sensitive Niosomes for Controlled Release and Hepatocellular Carcinoma Target Delivery of Tanshinone IIA

Contact Info

Product

Resources

About